HMG-CoA reductase inhibitors improve acute ischemic stroke outcome

126Citations
Citations of this article
63Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background and Purpose - Statins reduce the risk of stroke recurrence, but the benefits of statins in improving outcome of acute stroke patients have not been well explored. Methods - We assessed potential effects of statins initiated before or within 4 weeks of stroke on 90-day outcome. Favorable outcomes were National Institutes of Health Stroke Scale (NIHSS) score ≤2 at 12 weeks and modified Rankin Scale (mRS) ≤2. Results - Before stroke, 129 patients were receiving statins, 123 initiated statins within 4 weeks, and 600 patients were not on statins. Multivariate logistic regression analysis demonstrated that poststroke statins were associated with a significant probability of a favorable outcome at 12 weeks [NIHSS (P=0.002; OR, 1.92; CI, 1.27 to 2.91) and mRS (P=0.033; OR, 1.57; CI, 1.04 to 2.38)], whereas prestroke statins demonstrated a trend toward significance. Conclusions - These preliminary results suggest that statin use may improve outcome of acute ischemic stroke. © 2005 American Heart Association, Inc.

Author supplied keywords

Cite

CITATION STYLE

APA

Moonis, M., Kane, K., Schwiderski, U., Sandage, B. W., & Fisher, M. (2005). HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Stroke, 36(6), 1298–1300. https://doi.org/10.1161/01.STR.0000165920.67784.58

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free